TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03510845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL Primary Repair
Description: All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
Study: NCT03510845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic ACL Reconstruction
Description: Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
Study: NCT03023618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FloTrac
Description: Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
Study: NCT01270984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luckyvec 400mg film coated tablet
Description: •400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glivec 100mg film coated tablet
Description: •100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
Study: NCT00833495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 0.12% (Pred Mild®)
Description: Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 0.12% (Pred Mild®)
Description: Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOV1101-00
Description: This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOV1101-00
Description: This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% (Pred Forte®)
Description: PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
Study: NCT01448473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-views series
Description: The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-views serie
Description: The 2-film series will include the following views: anterior-posterior and one lateral.
Study: NCT01226784

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physcial activity
Description: Strenght training Relaxation exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physcial activity
Description: Strenght training Relaxation exercise
Study: NCT00872911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise
Description: progressive exercise training

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise
Description: progressive exercise training
Study: NCT01534442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
Study: NCT04128514

Intervention type: DEVICE
Intervention: Panoptix Toric
Description: Cataract surgery and IOL implantation
Study: NCT03425461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV
Study: NCT02283866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administering desflurane according to the patient's BIS value
Description: Administering desflurane according to the patient's BIS value

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administering desflurane at 1 MAC
Description: Administering desflurane at 1 MAC
Study: NCT01892072

Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study: NCT02967302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: active intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: active control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT04177758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients randomized to the control will receive a placebo
Study: NCT03119857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen+docetaxel
Description: Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary.
Study: NCT04111445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: IV infusion at Day 1 of each cycle
Study: NCT04158947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Study: NCT03425461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03538223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Participants will undergo two different types of music before radiotherapy sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Participants will undergo two different types of music before radiotherapy sessions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will undergo radiotherapy according to breast cancer post surgery protocol

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will undergo radiotherapy according to breast cancer post surgery protocol
Study: NCT01534442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02649842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS Toric Models ZCT450, ZCT525 or ZCT600
Description: Approved toric intraocular lens
Study: NCT02276755

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: 14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive placebo (Tishcon, USA) weekly.
Study: NCT02090348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Administered as specified in the treatment arm
Study: NCT04429789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-Alert Hypnosis
Description: Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Hypnosis
Description: Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
Study: NCT03198312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CathiportTM
Description: fully implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Port
Description: fully implanted
Study: NCT01633723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6886
Description: single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-6886
Description: DA-6886 placebo
Study: NCT01701817

Intervention type: OTHER
Intervention: Patients with Atrial Fibrillation
Description: Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
Study: NCT02004366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin once daily + correction doses of rapid acting insulin if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Bolus
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + 50% Glargine dose on discharge
Description: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + 80% Glargine
Description: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
Study: NCT00413946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin
Description: 3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: three doses of 1.0 ml saline per body weight
Study: NCT01921868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine
Description: Acetyl-L-Carnitine, 2 g/day, up to 24 months.
Study: NCT04601077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide lozenges, 30 mg
Description: Nitric Oxide lozenge, 30 mg twice a day for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
Study: NCT01482637

Intervention type: OTHER
Intervention: CAS
Description: All clients will be asked to complete the CAS instrument.
Study: NCT03531203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soursop supplementation
Description: The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group (without soursop group) was left without treatment during study period
Study: NCT01964222

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Description: Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
Study: NCT00840567

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw & sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw & sample
Study: NCT00115700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m2 I.V. on day 1

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 50 mg/m2 orally daily for days 1 - 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV Infusion day 1
Study: NCT01586143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03047668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet with/without supplementation
Description: diet with/without supplementation with PUFAs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet with/without supplementation
Description: diet with/without supplementation with PUFAs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet with/without supplementation
Description: diet with/without supplementation with PUFAs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet with/without supplementation
Description: diet with/without supplementation with PUFAs
Study: NCT03538223

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: All participants will undergo radiotherapy according to breast cancer post surgery protocol
Study: NCT00705614

Intervention type: BIOLOGICAL
Intervention: Remicade
Description: The treating physician will determine the treatment regimen and dose of Remicade.

Intervention type: BIOLOGICAL
Intervention: Remicade
Description: The treating physician will determine the treatment regimen and dose of Remicade.
Study: NCT00911872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen (EVOLENCE)
Description: injectable collagen
Study: NCT00777725

Intervention type: DEVICE
Intervention: FibroScan
Description: Liver scan, similar to an ultrasound.

Intervention type: DEVICE
Intervention: FibroScan
Description: Liver scan, similar to an ultrasound.

Intervention type: DEVICE
Intervention: FibroScan
Description: Liver scan, similar to an ultrasound.

Intervention type: DEVICE
Intervention: FibroScan
Description: Liver scan, similar to an ultrasound.
Study: NCT04988932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
Study: NCT04202120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Age-related stereotyping priming
Description: The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non age-related stereotype priming
Description: he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
Study: NCT01488136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazoxide
Description: Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
Study: NCT01986257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Group Therapy (ERGT).
Study: NCT01488136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Ph capsules (Placebo)
Study: NCT03143985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
Study: NCT04180657

Intervention type: GENETIC
Intervention: Protein C deficiency
Description: The effect of protein C deficiency on ghrelin levels are investigated.
Study: NCT04805723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.